Company updateMoneycontrol
ICICI Securities retains Buy on Alkem with Rs 6600 target
Positive+19
GreyOak summary
ICICI Securities maintained a Buy rating on Alkem Laboratories with a target price of Rs 6,600. The broker cut FY27-28E EPS estimates by 1-4% due to the Occlutech acquisition impact. Management guided for 11% India growth in FY27 despite margin pressure from the acquisition.
What it affects
- Alkem LaboratoriesALKEMPositive +19
Rolling sentiment Negative -42
Source
Read the original at MoneycontrolMore Alkem Laboratories news
- Alkem Labs Q2 net profit falls 14% to Rs 667 croreMoneycontrol · Results ·
- Alkem shares fall 3% after Q2 results; MOFSL retains Neutral ratingBusiness Standard · Results ·
- Motilal Oswal sets ALKEM target at Rs 5890Moneycontrol · Company update ·
- Alkem shares decline 2% as HSBC maintains Hold ratingMoneycontrol · Company update ·
- Alkem PAT down at ₹675 crore; biotech sales down 37%BusinessLine · Results ·